May. 22, 2020News & Opinions
The US Biomedical Advanced Research and Development Authority (BARDA) has added another illustrious European pharmaceutical industry player to the list of those whose resources it wants to tap to make a Covid-19 vaccine for the US.
May. 19, 2020News & Opinions
Anglo-Swedish drugmaker AstraZeneca has announced it will make as many as 30 million initial doses of a potential Covid-19 vaccine available by September this year, assuming the success of late-stage trials expected to conclude by mid-year.
Mar. 27, 2020News & Opinions
Anglo-Swedish drugmaker AstraZeneca has announced plans to collaborate with UK biotech Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for treating cardiovascular, renal, metabolic and ...
Dec. 06, 2019Topics
The chemical, pharmaceutical and life sciences industries in Switzerland — organized in the Scienceindustries trade association — account for 45% of total exports with around 70,000 employees and are thus the undisputed ...
Nov. 14, 2019News & Opinions
Major drugmaker AstraZeneca has announced plans to launch three initiatives in China to advance global R&D efforts. The plans include establishing global R&D and artificial intelligence (AI) innovation centers as well as creating a ...
Jun. 11, 2019News & Opinions
North America should continue to lead global pharmaceutical sales up to 2022, with $635 billion in revenue expected that year, drugmaker AstraZeneca said in a recently published outlook on the industry.
May. 08, 2019News & Opinions
Anglo-Swedish drugmaker AstraZeneca is to collaborate with French biotech Transgene, part of Institut Mérieux, to discover and develop immunotherapies for treating cancers and infectious diseases.
Apr. 03, 2019News & Opinions
In a move to accelerate the development of its oncology franchise, AstraZeneca has agreed a $6.9 billion deal with Japanese pharma major Daiichi Sankyo to share rights to a new breast cancer drug called DS-8201.
Dec. 14, 2018News & Opinions
US biopharma AVEO Oncology is collaborating with Anglo-Swedish drug major AstraZeneca on a combined treatment for liver cancer.
Nov. 14, 2018News & Opinions
Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion in cash and $500 million in Sobi ...
The latest information directly via newsletter.